EVis Bioscience AG

EVis Bioscience develops innovative gene delivery systems for targeted and personalized medicine. This includes extracellular vesicles, synthetic lipid nanoparticles, and their hybrids. Based in Zürich, the ETH spin-off aims to provide an alternative approach to viral vectors for treating genetic disorders. Further, the company offers sub-licenses of its vehicle to Pharma Companies and/or Research Labs that intend to develop gene-based formulations for specific medical applications. The BSL-Class 2 laboratory is equipped with • Microfluidics • Dynamic Light Scattering • Nanoparticle Tracking Analysis • Nano Flow Cytometry • Cell culture facilities • Advanced microscopy techniques and animal facilities through scientific collaboration with the University of Zürich For more information, please visit our website: www.evis-bioscience.com